SCHEMBL21990938

SCHEMBL21990938

O=C(Nc1ccc(F)c(Cl)c1)c1ccnc(N[S+]([O-])C2CCCCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
NPSR1 Q6W5P4 1/20 0.45
KCNQ3 O43525 1/20 0.44
KCNQ2 O43526 1/20 0.44
KCNE1 P15382 1/20 0.44
KCNQ1 P51787 1/20 0.44
MAOB P27338 2/20 0.43
MAOA P21397 1/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GSK3B P49841 4/20 0.42
MAPT P10636 4/20 0.42
GSK3A P49840 2/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991736 0.93 CCR2 (0.47) L3MBTL1NPC1RAB9AKCNQ3KCNQ2
SCHEMBL21014454 0.91 L3MBTL1 (0.45) L3MBTL1NPC1RAB9ANPSR1KCNQ3
SCHEMBL21014612 0.89 NPC1 (0.43) L3MBTL1NPC1RAB9ANPSR1KCNQ3
SCHEMBL21991185 0.88 KCNQ3 (0.44) L3MBTL1NPC1RAB9ANPSR1KCNQ3
SCHEMBL21991038 0.87 ALDH1A1 (0.46) L3MBTL1NPC1RAB9ANPSR1KCNQ3
SCHEMBL21991179 0.86 KCNQ3 (0.48) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL21991737 0.83 L3MBTL1 (0.47) L3MBTL1NPC1RAB9AKCNQ3KCNQ2
SCHEMBL21014410 0.83 MAOB (0.45) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL21991183 0.83 NPC1 (0.52) L3MBTL1NPC1RAB9AKCNQ3KCNQ2
SCHEMBL21991148 0.81 GRM4 (0.50) KCNQ3KCNQ2KCNE1KCNQ1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227262-B1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS INC (US) 2020-05-13 EP disclosed